Physician profile
Peter A Luongo
NPI 1376520940
$8,747.92
in general payments reported to CMS, 2019-2025
48 companies · $56.10 in 2025
The $56.10 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,134 · 2020: $1,545 · 2021: $1,529 · 2022: $1,416 · 2023: $1,681 · 2024: $386 · 2025: $56.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.56 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,744.62 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $995.78 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $544.63 | 2019-2024 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals Lp | $523.01 | 2019-2024 | Farxiga |
| Abbvie INC. | $453.60 | 2019-2023 | |
| Lilly USA, LLC | $425.26 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $407.59 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $266.59 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $257.22 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.34 | 2019-2023 | Trulance, Xifaxan, Cycloset |
| Kowa Pharmaceuticals America, INC. | $224.63 | 2019-2023 | Livalo, Seglentis |
| Exact Sciences Corporation | $215.41 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $209.63 | 2019-2022 | |
| Almatica Pharma LLC | $188.07 | 2022-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.10 | 2019-2023 | Jardiance |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Luongo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.